BioNTech SE
NASDAQ:BNTX
Intrinsic Value
BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. [ Read More ]
The intrinsic value of one BNTX stock under the Base Case scenario is 46.71 USD. Compared to the current market price of 87.73 USD, BioNTech SE is Overvalued by 47%.
Valuation Backtest
BioNTech SE
Run backtest to discover the historical profit from buying and selling BNTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
BioNTech SE
Current Assets | 19.5B |
Cash & Short-Term Investments | 16.5B |
Receivables | 2.3B |
Other Current Assets | 638.6m |
Non-Current Assets | 3.5B |
Long-Term Investments | 1.2B |
PP&E | 971.6m |
Intangibles | 1.2B |
Other Non-Current Assets | 164.7m |
Current Liabilities | 2.1B |
Accounts Payable | 354m |
Other Current Liabilities | 1.7B |
Non-Current Liabilities | 689.9m |
Long-Term Debt | 191m |
Other Non-Current Liabilities | 498.9m |
Earnings Waterfall
BioNTech SE
Revenue
|
3.8B
EUR
|
Cost of Revenue
|
-599.8m
EUR
|
Gross Profit
|
3.2B
EUR
|
Operating Expenses
|
-2.3B
EUR
|
Operating Income
|
908m
EUR
|
Other Expenses
|
22.3m
EUR
|
Net Income
|
930.3m
EUR
|
Free Cash Flow Analysis
BioNTech SE
BNTX Profitability Score
Profitability Due Diligence
BioNTech SE's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
Score
BioNTech SE's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
BNTX Solvency Score
Solvency Due Diligence
BioNTech SE's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
BioNTech SE's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BNTX Price Targets Summary
BioNTech SE
According to Wall Street analysts, the average 1-year price target for BNTX is 121.72 USD with a low forecast of 90.9 USD and a high forecast of 179.55 USD.
Shareholder Return
BNTX Price
BioNTech SE
Average Annual Return | 107.13% |
Standard Deviation of Annual Returns | 97.42% |
Max Drawdown | -80% |
Market Capitalization | 20.9B USD |
Shares Outstanding | 241 874 900 |
Percentage of Shares Shorted | 6.17% |
BNTX News
Last Important Events
BioNTech SE
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
BioNTech SE
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 3,082 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The company develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Contact
IPO
Employees
Officers
The intrinsic value of one BNTX stock under the Base Case scenario is 46.71 USD.
Compared to the current market price of 87.73 USD, BioNTech SE is Overvalued by 47%.